Exiqon enters licence agreement with IBA  

2004.05.10
The Danish biotech company Exiqon has signed a licence agreement with Germany's IBA concerning Exiqon's LNA technology

The Danish biotech company Exiqon has signed a licence agreement with Germany's IBA concerning Exiqon's Locked Nucleic Acid (LNA) technology. IBA has acquired non-exclusive rights to manufacture and sell LNA oligonucleotides for genomics research market and will receive know-how from Exiqon. Financial details of the agreement have not been disclosed.

 

Exiqon was founded in 1996 and is based in Vedbæk north of Copenhagen. Investors include Scandinavian Life Science Venture, Teknoinvest, Nobel Group and the Employees Capital Pension Fund. The news is reported by BiotechDenmark online and on Exiqon's website.

 

Link > Exiqon

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×